A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
Inclusion Criteria:
For the idiopathic pulmonary fibrosis (IPF) Cohort
For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Aurora, Colorado 80045, United States
Hamamatasu, Shizuoka 431-3192, Japan
Bunkyo-ku, Tokyo 113-8510, Japan
Minato-ku, Tokyo 1058470, Japan
Shinjyuku-ku, Tokyo 162-8655, Japan
Marbella Málaga, 29603, Spain